Skip to main content
SpringerLink
Log in

Quality by design: screening of critical variables and formulation optimization of Eudragit E nanoparticles containing dutasteride

  • Research Article
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

The study was aimed at screening, understanding, and optimizing product variability of dutasteride-loaded Eudragit E nanoparticles prepared by solvent displacement using Plackett–Burman screening and a central composite design. The independent process and formulation factors selected included: drug loading (%), solute concentration (mg/mL), Soluplus concentration (mg/mL), injection rate (mL/min), organic solvent type (methanol or ethanol), stirring rate (rpm), and organic-to-aqueous phase volume ratio. Among these factors, solute concentration was associated with increased particle size, broad particle size distribution, and enhanced entrapment efficiency. On the other hand, Soluplus concentration played a role in decreasing particle size, narrowing particle size distribution, and reducing entrapment efficiency. Other formulation and process factors did not have a significant impact on nanoparticle properties, assuming they were within the limits used in this study. The optimized formulation was achieved with 20 mg/mL solute and 3.22 mg/mL Soluplus, and the observed responses were very close to the values predicted using the response surface methodology. The results clearly showed that quality by design concept could be effectively applied to optimize dutasteride-loaded Eudragit E nanoparticles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Baek, I.H., and M.S. Kim. 2012. Improved supersaturation and oral absorption of dutasteride by amorphous solid dispersions. Chemical & Pharmaceutical Bulletin 60: 1468–1473.

    Article  Google Scholar 

  • Beck-Broichsitter, M., E. Rytting, T. Lebhardt, X. Wang, and T. Kissel. 2010. Preparation of nanoparticles by solvent displacement for drug delivery: A shift in the “ouzo region” upon drug loading. European Journal of Pharmaceutical Sciences 41: 244–253.

    Article  PubMed  CAS  Google Scholar 

  • Cha, K.-H., N. Lee, M.-S. Kim, J.-S. Kim, H.J. Park, J. Park, W. Cho, and S.-J. Hwang. 2010. Development and optimization of a novel sustained-release tablet formulation for bupropion hydrochloride using Box-Behnken design. Journal of Pharmaceutical Investigation 40: 313–319.

    Article  CAS  Google Scholar 

  • Chellampillai, B., and A.P. Pawar. 2011. Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles. European Journal of Drug Metabolism and Pharmacokinetics 35: 123–129.

    Article  PubMed  CAS  Google Scholar 

  • Dai, J.D., T. Nagai, X.Q. Wang, T. Zhang, M. Meng, and Q. Zhang. 2004. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. International Journal of Pharmaceutics 280: 229–240.

    Article  PubMed  CAS  Google Scholar 

  • Galindo-Rodriguez, S., E. Allémann, H. Fessi, and E. Doelker. 2004. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharmaceutical Research 21: 1428–1439.

    Article  PubMed  CAS  Google Scholar 

  • GlaxoSmithKline. Avodart®: Product Monograph http://www.gsk.ca/english/docs-pdf/product-monographs/Avodart.pdf, cited 1 December, 2012.

  • Hao, J., F. Wang, X. Wang, D. Zhang, Y. Bi, Y. Gao, X. Zhao, and Q. Zhang. 2012. Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design. European Journal of Pharmaceutical Sciences 47: 497–505.

    Article  PubMed  CAS  Google Scholar 

  • Jin, S.J., Y.H. Yoo, M.S. Kim, J.S. Kim, J.S. Park, and S.J. Hwang. 2008. Paroxetine hydrochloride controlled release POLYOX matrix tablets: Screening of formulation variables using Plackett–Burman screening design. Archives of Pharmacal Research 31: 399–405.

    Article  PubMed  CAS  Google Scholar 

  • Khachane, P., A.A. Date, and M.S. Nagarsenker. 2011. Eudragit EPO nanoparticles: Application in improving therapeutic efficacy and reducing ulcerogenicity of meloxicam on oral administration. Journal of Biomedical Nanotechnology 7: 590–597.

    Article  PubMed  CAS  Google Scholar 

  • Lee, Y.-L., M.-S. Kim, M.-Y. Park, and K. Han. 2012. Quality by design: Understanding the formulation variables and optimization of metformin hydrochloride 750 mg sustained release tablet by Box-Behnken design. Journal of Pharmaceutical Investigation 42: 213–220.

    Article  CAS  Google Scholar 

  • Legrand, P., S. Lesieur, A. Bochot, R. Gref, W. Raatjes, G. Barratt, and C. Vauthier. 2007. Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation. International Journal of Pharmaceutics 344: 33–43.

    Article  PubMed  CAS  Google Scholar 

  • Linn, M., E.M. Collnot, D. Djuric, K. Hempel, E. Fabian, K. Kolter, and C.M. Lehr. 2012. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. European Journal of Pharmaceutical Sciences 45: 336–343.

    Article  PubMed  CAS  Google Scholar 

  • Kim, M.-S., J.-S. Kim, Y.-H. You, H.J. Park, S. Lee, J.-S. Park, J.-S. Woo, and S.-J. Hwang. 2007. Development and optimization of a novel oral controlled delivery system for tamsulosin hydrochloride using response surface methodology. International Journal of Pharmaceutics 341: 97–104.

    Article  PubMed  CAS  Google Scholar 

  • Moinard-Checot, D., Y. Chevalier, S. Briancon, H. Fessi, and S. Guinebretiere. 2006. Nanoparticles for drug delivery: Review of the formulation and process difficulties illustrated by the emulsion-diffusion process. Journal of Nanoscience and Nanotechnology 6: 2664–2681.

    Article  PubMed  CAS  Google Scholar 

  • Molpeceres, J., M. Guzman, M.R. Aberturas, M. Chacon, and L. Berges. 1996. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. Journal of Pharmaceutical Sciences 85: 206–213.

    Article  PubMed  CAS  Google Scholar 

  • Myers, R.H., and D.C. Montgomery. 2002a. Response surface methodology: Process and product optimization using designed experiments, 321–342. New York: John Wiley & Sons.

    Google Scholar 

  • Myers, R.H., and D.C. Montgomery. 2002b. Response surface methodology: Process and product optimization using designed experiments, 273–286. New York: John Wiley & Sons.

    Google Scholar 

  • Quintanar-Guerrero, D., E. Allémann, H. Fessi, and E. Doelker. 1999. Pseudolatex preparation using a novel emulsion-diffusion process involving direct displacement of partially water-miscible solvents by distillation. International Journal of Pharmaceutics 188: 155–164.

    Article  PubMed  CAS  Google Scholar 

  • Rahman, Z., A.S. Zidan, M.J. Habib, and M.A. Khan. 2010. Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett–Burman design. International Journal of Pharmaceutics 389: 186–194.

    Article  PubMed  CAS  Google Scholar 

  • Singh, B., R. Bhatowa, C.B. Tripathi, and R. Kapil. 2011. Developing micro-/nanoparticulate drug delivery systems using “design of experiments”. International Journal of Pharmaceutical Investigation 1: 75–87.

    Article  PubMed  CAS  Google Scholar 

  • Tang, J., N. Xu, H. Ji, H. Liu, Z. Wang, and L. Wu. 2011. Eudragit nanoparticles containing genistein: Formulation, development, and bioavailability assessment. International Journal of Nanomedicine 6: 2429–2435.

    PubMed  CAS  Google Scholar 

  • Thorat, A.A., and S.V. Dalvi. 2012. Liquid antisolvent precipitation and stabilization of nanoparticles of poorly water soluble drugs in aqueous suspensions: Recent developments and future perspective. Chemical Engineering Journal 181–182: 1–34.

    Article  Google Scholar 

  • U.S. Food Drug Administration. Application Number: 21-319. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21319_Duagen_biopharmr_P1.pdf, cited 25 September, 2012.

  • Verma, S., V. Lan, R. Gokhale, and D.J. Burgess. 2009. Quality by design approach to understand the process of nanosuspension preparation. International Journal of Pharmaceutics 377: 185–198.

    Article  PubMed  CAS  Google Scholar 

  • Wang, X.Q., and Q. Zhang. 2012. pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. European Journal of Pharmaceutics and Biopharmaceutics 82: 219–229.

    Article  PubMed  CAS  Google Scholar 

  • Wu, H., M. White, and M.A. Khan. 2011. Quality-by-Design (QbD): An integrated process analytical technology (PAT) approach for a dynamic pharmaceutical co-precipitation process characterization and process design space development. International Journal of Pharmaceutics 405: 63–78.

    Article  PubMed  CAS  Google Scholar 

  • Wu, T.H., F.L. Yen, L.T. Lin, T.R. Tsai, C.C. Lin, and T.M. Cham. 2008. Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. International Journal of Pharmaceutics 346: 160–168.

    Article  PubMed  CAS  Google Scholar 

  • Xu, X., M.A. Khan, and D.J. Burgess. 2011. A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment. International Journal of Pharmaceutics 419: 52–59.

    Article  PubMed  CAS  Google Scholar 

  • Xu, X., M.A. Khan, and D.J. Burgess. 2012. A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. International Journal of Pharmaceutics 423: 543–553.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Engineering, Inje University, Gimhae, Gyeongnam, 621-749, Republic of Korea

    Se-Jin Park, Gwang-Ho Choo & Min-Soo Kim

  2. Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 162-1 Songdo-dong, Yeonsu-gu, Incheon, 406-840, Republic of Korea

    Sung-Joo Hwang

  3. College of Pharmacy, Yonsei University, 162-1 Songdo-dong, Yeonsu-gu, Incheon, 406-840, Republic of Korea

    Sung-Joo Hwang

Authors
  1. Se-Jin Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gwang-Ho Choo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sung-Joo Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Min-Soo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Min-Soo Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, SJ., Choo, GH., Hwang, SJ. et al. Quality by design: screening of critical variables and formulation optimization of Eudragit E nanoparticles containing dutasteride. Arch. Pharm. Res. 36, 593–601 (2013). https://doi.org/10.1007/s12272-013-0064-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-013-0064-z

Keywords

Search

Navigation